This segment focuses on the research and development of therapies for chronic hepatitis B and D infections. Vir Biotechnology is actively involved in clinical trials evaluating VIR-2218 and VIR-3434, both designed to address HBV. The company is also developing tobevibart, which has received Breakthrough Therapy Designation and PRIME designation for chronic hepatitis delta. Research and development activities include preclinical studies, Phase 1, 2, and 3 clinical trials, and collaborations with Gilead Sciences. The goal is to provide effective treatments and potentially functional cures for patients suffering from these debilitating liver diseases. Market positioning involves addressing unmet medical needs and offering innovative solutions. Future opportunities include expanding the pipeline and securing regulatory approvals. Partnerships with Gilead Sciences and others are crucial for advancing these therapies.

This segment concentrates on the development and commercialization of therapies to treat and prevent COVID-19. Vir Biotechnology's primary focus in this area is Sotrovimab (Xevudy), a SARS-CoV-2-neutralizing monoclonal antibody. Research and development activities include clinical trials to evaluate the efficacy and safety of Sotrovimab. The company has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the production of SARS-COV-2 antibodies. The patient impact is significant, as Sotrovimab provides a treatment option for those infected with COVID-19. Market positioning involves addressing the ongoing need for effective COVID-19 treatments. Future opportunities include exploring new applications and formulations of Sotrovimab. Regulatory aspects include obtaining approvals from health authorities worldwide. Partnerships with companies like GSK have been instrumental in advancing the development and commercialization of these therapies.

This segment is dedicated to the development of preventative measures against the influenza A virus. Vir Biotechnology is actively working on VIR-2482, a product candidate aimed at preventing influenza A infections. Research and development activities include preclinical studies and clinical trials to assess the safety and efficacy of VIR-2482. The therapeutic area covered is the prevention of influenza A, addressing a significant public health concern. The patient impact will be substantial, as VIR-2482 aims to reduce the incidence of influenza A infections. Market positioning involves providing a novel approach to influenza prevention. Future opportunities include expanding the pipeline and securing regulatory approvals. The company is likely to seek partnerships with pharmaceutical companies and research institutions to advance the development and commercialization of VIR-2482.

This segment focuses on the development of preventative measures against the human immunodeficiency virus (HIV). Vir Biotechnology is developing VIR-1111 for the prevention of HIV. Research and development activities include preclinical studies and clinical trials to assess the safety and efficacy of VIR-1111. The therapeutic area covered is the prevention of HIV, addressing a significant global health challenge. The patient impact will be substantial, as VIR-1111 aims to reduce the incidence of HIV infections. Market positioning involves providing a novel approach to HIV prevention. Future opportunities include expanding the pipeline and securing regulatory approvals. The company is likely to seek partnerships with pharmaceutical companies and research institutions to advance the development and commercialization of VIR-1111.